| scholarly article | Q13442814 |
| P50 | author | Michael A Schwarzschild | Q66922801 |
| P2093 | author name string | Jiang-Fan Chen | |
| Cornelis J Van der Schyf | |||
| Neal Castagnoli | |||
| Jacobus P Petzer | |||
| P2860 | cites work | Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains | Q61714001 |
| Localization of monoamine oxidases in human peripheral tissues | Q61849213 | ||
| Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues | Q63532989 | ||
| Adenosine A2A Antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in Parkinsonian monkeys | Q64905504 | ||
| Effect of lazabemide on the progression of disability in early Parkinson's disease. The Parkinson Study Group. | Q67243046 | ||
| Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680 | Q69362137 | ||
| Purification and properties of mitochondrial monoamine oxidase type A from human placenta | Q69969207 | ||
| Monoamine oxidase activity and distribution in marmoset brain: implications for MPTP toxicity | Q70401312 | ||
| The effect of age on the activity and molecular properties of human brain monoamine oxidase | Q71403787 | ||
| The striopallidal neuron: a main locus for adenosine-dopamine interactions in the brain | Q72640864 | ||
| Modulation of dihydroxyphenylacetaldehyde extracellular levels in vivo in the rat striatum after different kinds of pharmacological treatment | Q73634982 | ||
| Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat | Q74330160 | ||
| Overview of Parkinson's disease | Q80084640 | ||
| Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives | Q81683829 | ||
| Selegiline slows the progression of the symptoms of Parkinson disease | Q82843497 | ||
| Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis | Q22242250 | ||
| Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes | Q24563287 | ||
| Monoamine oxidase: from genes to behavior | Q24614980 | ||
| Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders | Q27637040 | ||
| Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures | Q27641832 | ||
| Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs | Q27648711 | ||
| Selective adenosine A2A receptor antagonists | Q28188402 | ||
| International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors | Q28209239 | ||
| Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats | Q28210110 | ||
| The FAD binding sites of human monoamine oxidases A and B | Q28236505 | ||
| Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications | Q28247343 | ||
| New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists | Q28258352 | ||
| The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets | Q28259381 | ||
| Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues | Q28291667 | ||
| Inhibition of monoamine oxidase B by analogues of the adenosine A2A receptor antagonist (E)-8-(3-chlorostyryl)caffeine (CSC) | Q28294306 | ||
| Cell surface monoamine oxidases: enzymes in search of a function | Q28345067 | ||
| The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice | Q28348761 | ||
| ??? | Q64867565 | ||
| ??? | Q64870231 | ||
| Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: a possible antioxidant strategy | Q28369605 | ||
| Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys | Q28374632 | ||
| Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP | Q28377464 | ||
| Parkinson's disease: mechanisms and models | Q29547424 | ||
| Biochemistry and genetics of monoamine oxidase | Q30420505 | ||
| Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum | Q30945230 | ||
| Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. | Q33537215 | ||
| Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. | Q33943891 | ||
| Monoamine oxidase expression during development and aging | Q33974871 | ||
| Effects of depression, cigarette smoking, and age on monoamine oxidase B in amygdaloid nuclei | Q34064063 | ||
| Association of coffee and caffeine intake with the risk of Parkinson disease | Q34508881 | ||
| Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. | Q34516364 | ||
| Adenosine A(2A) receptor antagonist treatment of Parkinson's disease | Q34536127 | ||
| Novel aspects of dopamine oxidative metabolism (confounding outcomes take place of certainties). | Q34553999 | ||
| Targeting adenosine A2A receptors in Parkinson's disease | Q34571644 | ||
| Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). | Q34756419 | ||
| Monoamine oxidase: radiotracer development and human studies | Q34786914 | ||
| Potential neurotoxic "agents provocateurs" in Parkinson's disease | Q34802021 | ||
| Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes | Q34802158 | ||
| Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness | Q35566604 | ||
| Translating A2A antagonist KW6002 from animal models to parkinsonian patients | Q35603282 | ||
| Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease | Q36057484 | ||
| Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline | Q36234729 | ||
| Alternatives to levodopa in the initial treatment of early Parkinson's disease | Q36255233 | ||
| Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons | Q36317322 | ||
| The therapeutic potential of monoamine oxidase inhibitors | Q36428042 | ||
| Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. | Q36767402 | ||
| Current pharmacotherapeutic treatment options in Parkinson's disease | Q36857140 | ||
| Medical management of levodopa-associated motor complications in patients with Parkinson's disease | Q36881415 | ||
| Disease-modifying drugs and Parkinson's disease | Q37013812 | ||
| Pharmacotherapy for Parkinson's disease. | Q37016031 | ||
| Monoamine oxidase-B inhibition in the treatment of Parkinson's disease | Q37016034 | ||
| Neuroprotection in Parkinson's disease: myth or reality? | Q37203405 | ||
| Oxidative stress: a role in the pathogenesis of Parkinson's disease | Q37935459 | ||
| Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition | Q39345051 | ||
| Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists | Q39386911 | ||
| Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia | Q39397431 | ||
| Amine oxidases and their endogenous substrates (with special reference to monoamine oxidase and the brain). | Q39595142 | ||
| Recent developments in the field of A2A and A3 adenosine receptor antagonists | Q40647461 | ||
| Tremulous jaw movements in rats: a model of parkinsonian tremor. | Q40830468 | ||
| Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia | Q41624006 | ||
| KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity | Q42283709 | ||
| Adenosine A1 antagonists. 3. Structure-activity relationships on amelioration against scopolamine- or N6-((R)-phenylisopropyl)adenosine-induced cognitive disturbance | Q42288287 | ||
| Human brain monoamine oxidase: multiple forms and selective inhibitors | Q42439481 | ||
| Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways. | Q42480222 | ||
| Monoamine oxidases of the human brain and liver | Q42514741 | ||
| Structure-activity relationships of 8-styrylxanthines as A2-selective adenosine antagonists | Q42558334 | ||
| Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. | Q43875632 | ||
| Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease | Q43922347 | ||
| Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial | Q44060104 | ||
| 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism | Q44072123 | ||
| Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists | Q44356897 | ||
| Caffeine, postmenopausal estrogen, and risk of Parkinson's disease | Q44357392 | ||
| Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. | Q44545760 | ||
| A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease | Q44668510 | ||
| A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease | Q44851007 | ||
| Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives | Q44865028 | ||
| Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence | Q45149466 | ||
| First visualization of adenosine A(2A) receptors in the human brain by positron emission tomography with [11C]TMSX. | Q45150561 | ||
| Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors | Q45264832 | ||
| Monoamine oxidases of the brains and livers of macaque and cercopithecus monkeys | Q46366136 | ||
| Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk | Q46911276 | ||
| Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys | Q48208543 | ||
| Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats | Q48267576 | ||
| Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. | Q48326584 | ||
| Distinct monoamine oxidase A and B populations in primate brain | Q48445611 | ||
| Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-1-aminoindan (rasagiline) in the monkey | Q48451474 | ||
| Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists | Q48561677 | ||
| Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors | Q48614146 | ||
| Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice | Q48655550 | ||
| Age-Related Increases in Brain Monoamine Oxidase B in Living Healthy Human Subjects | Q48662632 | ||
| Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study | Q48666967 | ||
| Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase | Q48681443 | ||
| Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats | Q48795844 | ||
| Monoamine oxidase-dependent metabolism of dopamine in the striatum and substantia nigra of L-DOPA-treated monkeys | Q48887246 | ||
| Multiple Forms of Human Brain Mitochondrial Monoamine Oxidase | Q48933366 | ||
| Multi-target-directed drug design strategy: from a dual binding site acetylcholinesterase inhibitor to a trifunctional compound against Alzheimer's disease | Q53290732 | ||
| Adenosine A1 and A2A receptor antagonists stimulate motor activity: evidence for an increased effectiveness in aged rats | Q55067854 | ||
| The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil | Q56484375 | ||
| Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes | Q59508508 | ||
| P433 | issue | 1 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 141-151 | |
| P577 | publication date | 2009-01-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Neurotherapeutics | Q15716631 |
| P1476 | title | Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease | |
| P478 | volume | 6 |
| Q64865864 | Q64865864 |
| Q84328130 | 5-(5-Aryl-1,3,4-oxadiazole-2-carbonyl)furan-3-carboxylate and new cyclic C-glycoside analogues from carbohydrate precursors with MAO-B, antimicrobial and antifungal activities |
| Q35166780 | 8-Benzyltetrahydropyrazino[2,1-f]purinediones: water-soluble tricyclic xanthine derivatives as multitarget drugs for neurodegenerative diseases. |
| Q37818990 | Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration |
| Q57708302 | Antiparkinsonian Effects of Novel Adenosine A2A Receptor Antagonists |
| Q42481890 | CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats |
| Q38022265 | Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis. |
| Q49109682 | Coffee consumption may influence hippocampal volume in young women |
| Q37852762 | Dual inhibition: a novel promising pharmacological approach for different disease conditions |
| Q36345411 | Equipotent Inhibition of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase – Dual Targets of the Endocannabinoid System to Protect against Seizure Pathology |
| Q28476804 | From L-dopa to dihydroxyphenylacetaldehyde: a toxic biochemical pathway plays a vital physiological function in insects |
| Q48875877 | Fusing Docking Scoring Functions Improves the Virtual Screening Performance for Discovering Parkinson's Disease Dual Target Ligands |
| Q38395423 | History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents |
| Q38631441 | Lessons from black pepper: piperine and derivatives thereof |
| Q39239178 | Molecular Docking and Prediction of Pharmacokinetic Properties of Dual Mechanism Drugs that Block MAO-B and Adenosine A(2A) Receptors for the Treatment of Parkinson's Disease. |
| Q90257355 | Novel, Dual Target-Directed Annelated Xanthine Derivatives Acting on Adenosine Receptors and Monoamine Oxidase B |
| Q35489240 | Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. |
| Q37981634 | Polycyclic Cage Structures as Lipophilic Scaffolds for Neuroactive Drugs |
| Q55547635 | Probing Substituents in the 1- and 3-Position: Tetrahydropyrazino-Annelated Water-Soluble Xanthine Derivatives as Multi-Target Drugs With Potent Adenosine Receptor Antagonistic Activity. |
| Q38447289 | Propargylamine as functional moiety in the design of multifunctional drugs for neurodegenerative disorders: MAO inhibition and beyond |
| Q36092174 | SVM Based Descriptor Selection and Classification of Neurodegenerative Disease Drugs for Pharmacological Modeling |
| Q38161850 | Selective MAO-B inhibitors: a lesson from natural products |
| Q35770449 | Structure-based design, synthesis, molecular docking, and biological activities of 2-(3-benzoylphenyl) propanoic acid derivatives as dual mechanism drugs |
| Q82667699 | The use of multi-target drugs in the treatment of neurodegenerative diseases |
| Q34139398 | Xanthines as Adenosine Receptor Antagonists |
| Q37693720 | mGluR4-positive allosteric modulation as potential treatment for Parkinson's disease. |
Search more.